Storage and handling
Store at room temperature (at or below 77F). Do not allow to freeze.
Toltramax 2.5% (2.5% toltrazuril suspension)
- Manufacturer
- Vetr, LLC | Alivira Animal Health
- Effective date
- 2026-10-02
- Label type
- OTC ANIMAL DRUG LABEL
- Version
- 3
- Source
- daily-update
- Hydrated at
- 2026-10-06 02:01:40
Label at a glance#
ProductToltramax 2.5% suspension
Active ingredientTOLTRAZURIL
Label structure6 sections
Label contents#
Full prescribing information#
WARNINGS AND PRECAUTIONS SECTION
Keep out of reach of children. Recognized as safe for use in pregnant and lactating females and puppies & kittens over four weeks of age.
DOSAGE & ADMINISTRATION SECTION
Shake well before use. Dose at 2 mL (50 mg toltrazuril) per 5 pounds of body weight, for 3-5 consecutive days. Toltramax should be administered orally and retreatment may be necessary after 4-6 weeks.
STORAGE AND HANDLING SECTION
Store at room temperature (at or below 77F). Do not allow to freeze.
OTC - ACTIVE INGREDIENT SECTION
Toltrazuril USP, 2.5% suspension (25 mg/mL)
INACTIVE INGREDIENT SECTION
Glycerin USP, methyl- and propylparaben (preservative), purified water.
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
Product Linked Resources#
| Resource | Code type | Value | Equivalent identifiers | Source image |
|---|---|---|---|---|
| QR code link | QR Code |  dosingcalculator.net/ | ToltraMax 1 gal 2.5_.jpg, ToltraMax 240ml 2.5_.jpg, ToltraMax 60ml 2.5_.jpg |
Products#
Every source-derived product name is available through these pages.
- Toltramax 2.5% suspension
- toltrazuril 2.5% suspension
- TOLTRAZURIL
- WATER
- GLYCERIN
- PROPYLPARABEN
- METHYLPARABEN
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 86213-122 | 86213-122-01, 86213-122-02, 86213-122-03, 86213-122-04, 86213-122-05 |
| 86213-123 | 86213-123-02, 86213-123-04 |
| 86213-124 | 86213-124-01, 86213-124-04 |
| 86213-121 | 86213-121-06, 86213-121-07, 86213-121-08 |
Ingredients#
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| TOLTRAZURIL | QVZ3IAR3JS | ACTIB |
| WATER | 059QF0KO0R | IACT |
| GLYCERIN | PDC6A3C0OX | IACT |
| PROPYLPARABEN | Z8IX2SC1OH | IACT |
| METHYLPARABEN | A2I8C7HI9T | IACT |
| TOLTRAZURIL | QVZ3IAR3JS | ACTIB |
| WATER | 059QF0KO0R | IACT |
| GLYCERIN | PDC6A3C0OX | IACT |
| PROPYLPARABEN | Z8IX2SC1OH | IACT |
| METHYLPARABEN | A2I8C7HI9T | IACT |
| TOLTRAZURIL | QVZ3IAR3JS | ACTIB |
| WATER | 059QF0KO0R | IACT |
| GLYCERIN | PDC6A3C0OX | IACT |
| PROPYLPARABEN | Z8IX2SC1OH | IACT |
| METHYLPARABEN | A2I8C7HI9T | IACT |
| TOLTRAZURIL | QVZ3IAR3JS | ACTIB |
| WATER | 059QF0KO0R | IACT |
| GLYCERIN | PDC6A3C0OX | IACT |
| PROPYLPARABEN | Z8IX2SC1OH | IACT |
| METHYLPARABEN | A2I8C7HI9T | IACT |
Source Document#
Older Hydrated Versions#
| Version | Effective date | Source | Hydrated |
|---|---|---|---|
| 2 | 2025-12-14 | full-release | 2026-06-01 02:45:33 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.